Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/175915| Title: | Unraveling the role of fibroblasts, FGF5 and FGFR2 in HER2-targeted therapies resistance and tumor progression |
| Author: | Bragado, Paloma Fernández-Nogueira, Patricia Carbó Carbó, Neus Gascón, Pere |
| Keywords: | Fibroblasts Càncer Fibroblasts Cancer |
| Issue Date: | 8-Dec-2020 |
| Publisher: | Impact Journals |
| Abstract: | The majority of women with HER2-positive breast cancer will initially respond to trastuzumab and/or other HER2-targeted therapies such as pertuzumab, lapatinib, neratinib and trastuzumab emtansine (T-DM1). However [...]. |
| Note: | Reproducció del document publicat a: https://doi.org/10.18632/oncotarget.27829 |
| It is part of: | Oncotarget, 2020, vol. 11, num. 49, p. 4541-4543 |
| URI: | http://hdl.handle.net/2445/175915 |
| Related resource: | https://doi.org/10.18632/oncotarget.27829 |
| ISSN: | 1949-2553 |
| Appears in Collections: | Articles publicats en revistes (Bioquímica i Biomedicina Molecular) |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| 710528.pdf | 1.13 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License
